收藏切换
Value of nabuliumab combined with ipilimumab in the treatment of locally advanced lung adenocarcinoma
收藏切换
Bing YU, Meng ZHANG, Fei GUO, Huiting LI
World Clinical Drug | 2024, 45(1) : 26 - 31
Less
收藏切换
World Clinical Drug | 2024, 45(1): 26-31
• Article •
Value of nabuliumab combined with ipilimumab in the treatment of locally advanced lung adenocarcinoma
Full
Bing YU, Meng ZHANG, Fei GUO, Huiting LI
Affiliations
  • Department of Respiratory and Critical Care Medicine, Yantai Affiliated Hospital of Binzhou Medical University (the Second School of Clinical Medicine of Binzhou Medical University), Binzhou 264100, Shandong Province, China
Published: 2024-01-10 doi: 10.13683/j.wph.2024.01.005
Outline
收藏切换
Objective

To evaluate the efficacy and safety of nabuliumab combined with ipilimumab in the first-line treatment of locally advanced lung adenocarcinoma.

Methods

Ninety-two patients with locally advanced lung adenocarcinoma were randomly divided into control group and combined group by random number table method, 46 cases in each group. The control group received pemetrexed combined with cisplatin, and the combined group received nabuliumab combined with ipilimumab. Disease control rate (DCR), objective response rate (ORR), safety, tumor downstaging rate, major pathological response (MPR), pathological complete response (pCR) rate and tumor markers were compared between the two groups.

Results

The rates of ORR, DCR, tumor downstaging in the combined group were higher than those in the control group (P<0.05), and the incidence of adverse reaction in grade Ⅲ and above was lower than that in the control group (P<0.05). After 2 months of treatment, serum carcino-embryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (Cyfra21-1) and neurone-specific enolase (NSE) levels in 2 groups were decreased compared with those before treatment (P<0.05), and serum CEA, Cyfra21-1 and NSE levels in combined group were significantly lower than those in control group (P<0.05).

Conclusion

Nabuliumab combined with ipilimumab in the first-line treatment of locally advanced lung adenocarcinoma can increase ORR, DCR, tumor descending stage rate, and the adverse reactions are controllable.

nivolumab  /  ipilimumab  /  locally advanced lung adenocarcinoma  /  immunotherapy
于冰, 张蒙, 郭飞, 李慧婷. 纳武利尤单抗联合伊匹木单抗治疗局部晚期肺腺癌的价值. 世界临床药物, 2024 , 45 (1) : 26 -31 . DOI: 10.13683/j.wph.2024.01.005
Bing YU, Meng ZHANG, Fei GUO, Huiting LI. Value of nabuliumab combined with ipilimumab in the treatment of locally advanced lung adenocarcinoma[J]. World Clinical Drug, 2024 , 45 (1) : 26 -31 . DOI: 10.13683/j.wph.2024.01.005
Year 2024 volume 45 Issue 1
17
5
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.01.005
  • Receive Date:2023-02-28
  • Online Date:2026-11-18
  • Published:2024-01-10
Article Data
Affiliations
History
  • Received:2023-02-28
  • Revised:2023-09-10
Funding
Affiliations
    Department of Respiratory and Critical Care Medicine, Yantai Affiliated Hospital of Binzhou Medical University (the Second School of Clinical Medicine of Binzhou Medical University), Binzhou 264100, Shandong Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.01.005
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT